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TCR genemodified T cells for adoptive therapy simultaneously express the Tg TCR and the
endogenous TCR, which might lead to mispaired TCRs with harmful unknown specificity
and to a reduced function of TCR-Tg T cells. We generated dual TCR T cells in two
settings in which either TCR was constitutively expressed by a retroviral promoter while
the second TCR expression was regulable by a Tet-on system. Constitutively expressed
TCRmoleculeswere reduced on the cell surface depending on the induced TCR expression
leading to strongly hampered function. Besides that, using fluorescence resonance energy
transfer we detected mispaired TCR dimers and different pairing behaviors of individual
TCR chains with a mutual influence on TCR chain expression. The loss of function and
mispairing could not be avoided by changing the TCR expression level or by introduction
of an additional cysteine bridge. However, in polyclonal T cells, optimized TCR formats
(cysteineization, codon optimization) enhanced correct pairing and function.We conclude
from our data that (i) the level of mispairing depends on the individual TCRs and is
not reduced by increasing the level of one TCR, and (ii) modifications (cysteineization,
codon optimization) improve correct pairing but do not completely exclude mispairing
(cysteineization).
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Introduction
The adoptive transfer of TCR gene-modified T cells showed first
clinical success in the treatment of melanoma and synovial sar-
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coma [1, 2]. But also detrimental effects of TCR gene therapy
became obvious as on-target toxicity was observed in two clini-
cal trials due to tumor-associated Ag expression on healthy tissue
[3,4]. In addition, off-target side effects can potentially occur due
to TCR gene transfer that creates dual TCR T cells with mispaired
TCR dimers harboring the risk to recognize self-antigens. Although
in patients treated by TCR gene therapy such toxicity was not
reported so far, lethal autoimmune pathology due to mispaired
C© 2013 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH &
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TCR dimers was seen in a mouse model in which animals received
TCR-Tg T cells using a protocol mimicking clinical application [5].
The application of T-cell populations with unique TCR specificity
(e.g. virus-specific T-cell clones) may limit the formation of mis-
paired TCR dimers. However, also in this setting, mispaired TCRs
were formed with potentially hazardous specificities recognizing
both allo- and auto-Ags in a HLA class I and II restricted fashion
[6].
Therefore, efforts have been made to diminish the occurrence
of mispaired TCR dimers. First, the stoichiometric expression of
the TCRα and TCRβ chain genes can be improved by using a
viral peptide linker instead of an internal ribosomal entry site in
the transgene cassette [7–9]. Second, numerous modifications of
the TCR gene sequence were performed to reduce the formation
of mispaired TCRs [10–16]; reviewed in [17]. Two of the most
often utilized modifications are the replacement of the human
TCR constant (C-) regions by the mouse counterparts (muriniza-
tion) [12, 18, 19] and the insertion of a second cysteine bridge
(cysteineization) into the TCR C-region [13, 14]. Especially, cys-
teineization reduced the incidence of autoimmunity in a mouse
model [5] and the appearance of neoreactivities in vitro [6].
A more general approach is the codon optimization of the TCR
genes that improves the expression of most if not all Tg TCRs and
thereby limits those of the endogenous ones [7].
Little is known about the quantitative relationship between
endogenous and transferred TCRs with respect to surface expres-
sion of individual TCR chains, function, and pairing. We generated
dual TCR-expressing T cells by gene transfer of two model TCRs
into mouse 58 T cells harboring no endogenous TCR molecules or
by transfer of one TCR into WT T cells to study surface expression,
function, and pairing of unmodified ormodified TCRs (cysteineiza-
tion, codon optimization). To analyze pairing, we utilized fluores-
cence resonance energy transfer (FRET) — a method that allows
the determination of the regional proximity of two molecules by
labeling with suitable fluorophores.
Results
TCR expression is inducible by a Tet-regulated
retrovirus SIN vector
The P14 TCR, specific for the glycoprotein (gp33) of the lympho-
cytic choriomeningitis virus, and the OVA-specific OT-I TCR were
expressed by a doxycycline (Dox, Tet)-regulated gammaretrovirus
SIN vector [20] in 58 cells [21], which do not express an endoge-
nous TCR. By adding Dox concentrations from 0.01 to 1.0 μg/mL
for 24 h, TCR expression was achieved in T-cell clones (P14ind and
OT-Iind) measured by flow cytometry (Fig. 1A–D). We determined
the kinetics of inducibility and measured already 4 h after addi-
tion of 1 μg/mL Dox P14 and OT-I TCR expression that reached
its maximum at 16 h and remained stable until 24 h. After depri-
vation of Dox, expression of both TCRs decreased within 24 h and
was no longer detectable after 72 h (Fig. 1E). For analysis of Tet-
regulated TCR-mediated functionality, TCRind T-cell clones were
co-cultured with splenocytes loaded with cognate peptide. OT-Iind
Figure 1. Inducible TCR expression in single TCR-Tg T cells. T-cell
clones expressing P14ind or OT-Iind TCR were seeded at a density of
4 × 105/mL and incubated for 24 h with different concentrations of
Dox. TCR expression was analyzed by flow cytometry and living cells
discriminated in FSC/SSC dot plot. Dot plot of (A) P14ind or (B) OT-Iind
living cells stained for TCR chains. (C) Percentages or (D) MFI of TCRvα
and TCRvβ chain double-positive cells as a function of Dox concentra-
tion. (E) Percentage of TCR-positive cells as a function of incubation
time in presence of Dox (1 μg/mL). (C–E) Data are shown as mean ± SD
(n = 3–6) and are pooled from at least three independent experiments.
(F) Co-cultivation of Dox-induced TCR-expressing 58 T cells with irra-
diated C57BL/6 splenocytes loaded with 10 μM peptide (gp33–41 for P14
TCR and OVA257–264 for OT-I TCR). As a control no peptide (w/o) or an
unspecific stimulus with PMA and ionomycin (max) was added. IL-2
amount was determined by ELISA. Bars indicate mean of duplicates
and mean deviation. One representative experiment of two is shown.
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T cells already secreted IL-2 when TCR expression was induced
with 0.005 μg/mL Dox (Fig. 1F), although at this concentration
almost no TCR expression was observed (Fig. 1C). Addition of
Dox between 0.01 and 1.0 μg/mL yielded similar amounts of
IL-2. IL-2 secretion of P14ind T cells was detectable after addition
of 0.01 μg/mL Dox and increased with higher Dox concentrations
(Fig. 1F).
These data indicate that using the Tet-regulated vector we
achieved different TCR expression levels and TCR function
depending on the Dox concentration.
Gain of function of one TCR is accompanied by loss
of function of the second TCR
To analyze the interrelationship of two TCRs, we generated
dual TCR-Tg 58 T cells in which one TCR was expressed under
the control of the constitutive promoter of the retroviral vector
LXSN, while the expression of the second TCR was Dox-inducible
(Fig. 2A).
In the first setting, the OT-I TCR was constitutively expressed
in 58 T cells and the P14 TCR expression was induced (OT-
Icon/P14ind; where con is constitutive expression and ind is induced
expression) using different Dox concentrations (no Dox – “off,”
0.05 μg/mL – “med,” 1.0 μg/mL – “high”). P14 TCR expression
increased as a function of Dox concentration from 71% (med)
to 96% (high) (Fig. 2B). The increasing percentage of P14 TCR
molecules on the cell surface did not influence the percentage of
the cells constitutively expressing OT-I TCR since this was 98% at
med and high Dox concentrations. However, the number of TCR
molecules per cell as measured by MFI decreased for the OT-Ivα2
chain from 51 (off) to 30 (high) (by 41%) and for the OT-Ivβ5
chain from 17 (off) to 13 (high) (by 24%). TCR molecules on
the cell surface were quantified more precisely with secondary
FITC Ab and with the help of calibrated FITC-labeled beads. This
method revealed a decrease of 49 ± 29% for OT-Ivα2 chain and
57 ± 7% for the OT-Ivβ5 chain (Fig. 2C).
In parallel to the decrease of OT-I TCR molecules, we observed
a gradual decrease in its function as measured by IL-2 release after
co-cultivation with OVA peptide-loaded splenocytes whereas the
induced P14 TCR gained function (Fig. 2D).
In the second setting, the P14 TCR was constitutively
expressed, while the expression of the OT-I TCR was induced
(P14con/OT-Iind). Here, the OT-I TCR expression increased
depending on Dox concentration from 68% (med) to 87% (high).
In parallel, the expression of the P14 TCR slightly decreased from
99 to 93% (Fig. 2F) as well as the MFI of P14vα2 chain from
71 (off) to 23 (high) (by 68%) and of P14vβ8 chain from 23 (off)
to 13 (high) (by 44%). The quantification confirmed the decrease
of TCR molecules, namely 63 ± 18% for P14vα2 and 39 ± 13%
for P14vβ8 (Fig. 2G). The reduced expression of the P14 TCR was
accompanied by a complete loss of its function, while the induced
OT-I TCR expression resulted in a gain of function (Fig. 2H).
Although dual TCR T cells appear to present both TCRs, the
reduction of TCR molecules by ∼50% on the cell surface is suffi-
cient to reduce or completely shut down IL-2 secretion after TCR
trigger depending on the influence of the second TCR.
Formation of mispaired TCR dimers contributes to the
diminished TCR function
Beside reduced levels of TCR molecules on the cell surface, we
assumed that mispairing of TCR chains contributed to the loss
of function of the TCRcon. FRET measurements for the detection
of the occurrence of mispaired TCR dimers were performed. In
OT-Icon/P14ind 58 T cells, the FRET efficiency of the constitu-
tively expressed OT-I TCR stayed at a similar level (33.7 ± 5%
no Dox vs. 32.5 ± 8% high Dox) even when P14 TCR expres-
sion was induced in 85.9 ± 9% TCR-positive cells (Fig. 2E). The
induced P14 TCR did not have a significant lower FRET efficiency
of 23.3 ± 8% with high Dox concentration compared to the OT-I
TCR, which was similar to the FRET efficiency of OT-Ivα2/P14vβ8
(22.6 ± 8%). The mispaired TCR dimer P14vα2/OT-Ivβ5 showed
a significant lower FRET efficiency of 12 ± 7% compared to OT-I
and P14 TCR. These data show that there is a considerable degree
of OT-I and P14 TCR mispairing with a preference for the occur-
rence of OT-Ivα2/P14vβ8 dimers. The FRET efficiency of the OT-I
TCR that stayed stable with Dox is reflected by the occurrence
of equal amounts of corresponding TCR chains. Quantification of
TCR chains showed a similar decrease or increase of OT-Icon or
P14ind molecules, respectively, for OT-Ivα2 from 1830 ± 480 to
940 ± 360; OT-Ivβ5 from 1910 ± 210 to 820 ± 130 and for
P14vα2: 1670 ± 460; P14vβ8: 1850 ± 560 with 1 μg/mL Dox
(Fig. 2C). Nevertheless, this did not exclude the occurrence of
mispaired TCR dimers.
In P14con/OT-Iind 58 T cells, the FRET efficiency measured for
P14 TCR significantly decreased from 35 ± 3 to 19 ± 6% when
the OT-I TCR was induced with high Dox concentration (76.4 ±
17% TCR-positive cells) (Fig. 2I). The FRET efficiency of correct
OT-I TCR pairing was 25 ± 6%. Again, a preference was noted for
the mispaired TCR dimer comprising of OT-Ivα2/P14vβ8 (21 ±
8%) and not P14vα2/OT-Ivβ5 (12 ± 3%). The reduced FRET effi-
ciency of the P14 TCRwith Dox was also confirmed by the unequal
decrease of the corresponding TCR chain molecules (P14vα2 from
4360 ± 1080 to 1600 ± 780; P14vβ8 from 3200 ± 440 to
1970 ± 400) and the unequal induction of OT-I TCR with Dox
(OT-Ivα2: 1280 ± 680 and OT-Ivβ5: 830 ± 50) (Fig. 2G). In sum,
these cells harbored mispaired TCR dimers and a reduced capa-
bility of prober P14 TCR pairing.
Similar results were obtained in both models when med Dox
concentrations were applied (data not shown). Tetramer staining
to dissect proper TCR formation was not possible with the 58
T-cell line due to unspecific binding of tetramer to the transferred
CD8α molecule that was needed for the functional analysis of the
TCRs. Unspecific tetramer binding could not be blocked by CD8α
antibody.
In summary, FRET analysis of both TCR combinations indicated
that the TCR dimer OT-Ivα2/P14vβ8 occurred to a similar level
as the correctly paired P14 and OT-I TCR. Thus, the detected
mispaired TCRs as well as the reduced TCR molecules on the cell
C© 2013 The Authors. European Journal of Immunology published
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Figure 2. Analysis of TCR expression, functionality, and TCR mispairing in dual TCR T cells. (A) Schematic picture of the generation of dual TCR
T cells. Fifty-eight T cells (4 × 105/mL) were incubated for 24 h with 1 μg/mL (high), 0.05 μg/mL (med), or without (off) Dox. Dot plots of cells stained
for (B) constitutively expressed OT-I TCR and induced P14 TCR (OT-Icon/P14ind) or for (F) constitutively expressed P14 TCR and induced OT-I TCR
(P14con/OT-Iind). (B, F) Bold numbers indicate MFI. Quantification of TCR chains in (C) OT-Icon/P14ind cells and (G) P14con/OT-Iind cells. Antibody
binding capacity (ABC) represents molecules on cell surface. (C, G) Data are shown as mean ± SD (n = 3) and are pooled from three independent
experiments. IL-2 secretion as a function of constitutive and induced TCR expression in (D) OT-Icon/P14ind cells and (H) P14con/OT-Iind cells after
24 h co-cultivation with gp33/OVA peptide-loaded splenocytes. IL-2 amount, measured by ELISA, is given as percentage of the maximal secretion,
which was determined for TCRind at 10 μM cognate peptide and high Dox (P14ind: 63 pg/mL; OT-Iind: 141 pg/mL) and for TCRcon at 10 μM cognate
peptide and without Dox (OT-Icon: 82 pg/mL; P14con: 103 pg/mL). Data points indicate mean of duplicates and mean deviation. For B, D, F, H one
representative experiment of three or more is shown. FRET analysis of correctly and mispaired TCRs on dual TCR (E) OT-Icon/P14ind cells and
(I) P14con/OT-Iind cells. (E, I) Data are shown as mean + SD (n = 3–5) and are pooled from at least three independent experiments. *p < 0.05,
**p < 0.01, ***p < 0.001; unpaired Student’s t-test.
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Figure 3. Induction of single OT-I TCR chains in dual 58 T cells.
T cells (4 × 105/mL) were incubated for 24 h with 1 μg/mL (high)
or without (off) Dox. TCR chain staining of P14 and (A) P14vβ8/
OT-Ivα2 (P14con/OT-Ivα2ind) or (B) P14vα2/OT-Ivβ5 (P14con/OT-Ivβ5ind) is
shown as dot plots. One of three experiments is shown. Bold num-
bers indicate MFI. (C) FRET analysis of correctly and mispaired TCRs
on P14con/OT-Ivα2ind or vβ5ind cells. Data are shown as mean ± SD (n
= 3) and are pooled from three independent experiments. *p < 0.05,
**p < 0.01; unpaired Student’s t-test.
surface of the constitutively expressed TCR in both T-cell clones
explain the reduction or even loss of function of either the OT-I
or the P14 TCR. The different pairing behavior of TCR chains also
influences the expression of the corresponding TCR chain on the
cell surface, which was seen to be unequal in P14con+OT-Iind cells.
To further confirm the occurrence of mispaired TCRs, P14con
T-cell clones with single inducible OT-I TCR chains were con-
structed. Induced OT-Ivα2 TCR chain expression led to a decrease
from 96 to 76% P14 TCR-positive cells (P14con/OT-Ivα2ind), which
was due to the partial loss of P14vα2 TCR chain expression (MFI
decreased by 61% from 38 to 15) (Fig. 3A). The induced OT-Ivα2
paired with the P14vβ8 TCR chain (89%) and therefore, partially
displaced the P14vα2 chain. Induction of the OT-Ivβ5 TCR chain
expression diminished P14 TCR-positive cells from 96 to 46%
(P14con/OT-Ivβ5ind) and formed with the P14vα2 TCR chain 59%
double-positive T cells thereby partially replacing the P14vβ8
chain (MFI decreased by 41% from 22 to 13) (Fig. 3B). FRET effi-
ciency of the endogenous P14 TCRwas significantly reduced when
the OT-Ivα2 TCR chain was induced (27 ± 8 vs. 10 ± 4%), but not
when the OT-Ivβ5 TCR chain was induced (27 ± 8 vs. 26 ± 3%)
(Fig. 3C). The mispairing of the OT-Ivα2 with the P14vβ8 chain
showed a FRET efficiency of 16 ± 4%, which was significantly
lower as themispairing of the P14vα2 chainwith theOT-Ivβ5 chain
(28 ± 5%). These results demonstrate that both inducible single
OT-I TCR chains can partially replace their P14 TCR chain coun-
terparts, but that the inducible OT-Ivα2 chain reduces pairing
of the P14 TCR by pairing with the P14vβ8 chain more easily,
whereas the OT-Ivβ5 chain showed an equal pairing efficiency
to the P14vα2 as P14vβ8. These data confirmed the differential
pairing behavior of individual TCR chains.
A second cysteine bridge in P14 TCR does not prevent
the formation of mispaired TCR dimers
Since proper P14 TCR chain pairing was strongly impaired by the
induced OT-I TCR, we modified the P14 TCR by cysteineization
[13, 14] and generated two T-cell clones expressing P14cys and
OT-Iind TCRs (P14cyscon+OT-Iind). Induction of OT-I TCR expres-
sion in cl.9 (P14cyscon/OT-Iind cl.9) (96%) decreased the per-
centage of P14cys TCR-positive cells from 96 to 68% (Fig. 4A).
In parallel, we measured a complete loss of function of the
P14cys TCR (Fig. 4B). In the second 58 T-cell clone (P14cyscon/
OT-Iind cl.7), moderate OT-I TCR expression was induced (57%)
(Fig. 4D). Here, the induction of OT-I TCR expression did not
diminish the percentage of P14 TCR-positive cells (97% vs. 96%)
but again led to a complete loss of function of the P14cys TCR
(Fig. 4E).
Independently of the strength of the OT-I TCR induction, TCR
mispairing was detected by FRET similarly (Fig. 4C and F) as in
the noncysteineized P14con+OT-Iind cells (Fig. 2I), but moderate
induced OT-I TCR expression in cl.7 could not reduce P14 prober
pairing as highly as induced OT-I TCR expression in cl.9.
Nevertheless, these data indicate that neither the expression
level of the OT-I TCR nor the introduction of a cysteine modifica-
tion into the P14 TCR C-region could rescue the function of the
P14 TCR and prevent mispairing in this dual TCR T-cell model.
The combination of different TCR modifications
improves P14 TCR chain pairing
So far, our results indicate that cysteineization of the P14 TCR
did not prevent mispairing with OT-I TCR chains in a model T-cell
line. To analyze these modified TCRs in a more clinically relevant
situation, primary polyclonal T cells were transduced. Beside cys-
teineization, also codon optimization was included as TCR format
[7]. In C57BL/6 primary mouse T cells, the expression level of WT
and cysteineized TCR formats could be considerably increased
by codon optimization (Fig. 5A). To analyze whether these
C© 2013 The Authors. European Journal of Immunology published
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Figure 4. Cysteineization of P14 TCR in dual TCR T cells. Fifty-eight T cells (4 × 105/mL) were incubated for 24 h without (off) or with 1 μg/mL
(high) Dox and stained for constitutive cysteine-modified P14 (P14cys) TCR and induced OT-I TCR expression, P14cyscon/OT-Iind cl.9 (A) and cl.7
(D). IL-2 secretion in dual TCR 58 T cells as function of constitutive P14cys TCR and induced OT-I TCR expression, cl.9 (B) and cl.7 (E). IL-2
amount is given as percentage of the maximal secretion, which was determined for OT-Iind at 10 μM OVA peptide and high Dox (cl.9: 257 pg/mL;
cl.7: 321 pg/mL) and for P14cyscon at 10 μM gp33 peptide and without Dox (cl.9: 101 pg/mL; cl.7: 313 pg/mL). Data points indicate mean of duplicates
and mean deviation. (A, B, D, E) One representative experiment of three is shown. FRET analysis of correctly and mispaired TCRs on dual TCR
P14cyscon/OT-Iind cl.9 (C) and cl.7 (F). (C, F) Data are shown as mean ± SD (n = 3) and are pooled from three independent experiments. *p < 0.05,
**p < 0.01; unpaired Student’s t-test.
differences also apply to TCR function, a co-cultivation of equili-
brated numbers of TCR-Tg T cells with peptide-loaded splenocytes
was performed. No difference in IFN-γ release was found for the
different TCR formats at higher peptide concentrations (100 and
10 pM). However, at lower peptide concentrations (1 pM), the
modified TCR formats, especially those of the OT-I TCR, showed
a higher function in comparison to the WT TCRs (Fig. 5B). In 58
T cells, the differences in function of these TCR formats were not
observed (Supporting Information Fig. 1). Moreover, the expres-
sion level of the different TCR formats on splenocytes directly
correlated with small (not significant) differences in FRET effi-
ciencies, which were more pronounced for the P14 TCR than
for the OT-I TCR (Fig. 5C). These results demonstrate that the
combination of TCR modifications improves correct TCR pairing
on polyclonal T cells and that the level of improvement is TCR
dependent.
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Figure 5. Primary C57BL/6 T cells transduced with different formats of
P14 or OT-I TCRs. (A) C57BL/6 splenocytes were retrovirally transduced
with different formats of the P14 (above) and OT-I TCR (below) and
transduction rates were determined by TCR staining (P14: vβ8/vα2-Myc-
Tag; OT-I: vβ5/vα2-HA-Tag). Live cells were discriminated in FSC/SSC
dot plot. (B) IFN-γ secretion of primary C57BL/6 T cells transduced
with the P14 (above) or OT-I TCR (below) after 24 h co-cultivation with
peptide-loaded splenocytes. Bars indicate mean of triplets and mean
deviation. (C) FRET efficiencies were calculated from staining as shown
in (A). The mean and mean deviation of two separate measurements
was determined. (A–C) Data shown are representative for one experi-
ment out of three performed. *p < 0.05; **p < 0.01; ***p < 0.001; unpaired
Student’s t-test. cys: cysteineized-TCR with second cysteine bridge; co:
codon-optimized TCR; cocys: codonoptimized and cysteineized TCR.
Discussion
In this study, we generated dual TCR T cells for a detailed analysis
of the interaction between two TCRs under defined conditions.
The expression level of the transduced TCRs was regulated either
by using the constitutive promoter of the long terminal repeat
of the retroviral vector LXSN [22] or the all-in-one vector Tet-on
system [20] that offers the advantage to express all components of
the Tet system from a single retroviral vector, with a good signal-
to-noise ratio. Using the Tet-on vector system, we showed that the
expression of both TCRs was inducible. To achieve a high TCR
expression level, we used a Dox concentration of 1 μg/mL. For a
low TCR expression level, we used 0.05 μg/mL Dox resulting in
50–60% TCR-positive cells. Lower Dox concentrations yielded a
very low TCR expression (10–15%) and were considered as not
suitable for our dual TCR expression analysis.
After induced TCR expression, we found that the constitutively
expressed TCR remained on the cell surface but in lower numbers
leading to a complete (P14 TCR) or partial (OT-I TCR) loss of
function. That the expression of one TCR in dual TCR T cells can be
reduced or lost was reported previously [23–26]. Another reason
for this hampered function is the formation of mispaired TCR
dimers. The occurrence of TCR mispairing was shown indirectly
by not correlating TCRvβ chain and multimer staining in TCR-
transduced T cells [9,11,27,28]. In our study, multimer staining
of the 58 cells (+CD8α) was not possible. In one report, FRET
analysis was applied to quantify the improved pairing after the
introduction of the CD3ζ into the TCR sequence [11]. In another
study, TCR chain pairing measured by FRET was compared in
HeLa and Jurkat cells [29]. This study is hampered by the fact
that HeLa cells lack CD3 components, which have an impact on
TCR pairing [30].
We also investigated correct pairing and mispairing of TCRα
and β chains in dual TCR T cells by FRET. Besides correctly paired
P14 and OT-I TCRs, we determined considerable occurrence of
mispaired TCR dimers that was confirmed by the transfer of either
the Tet-inducible TCR OT-Ivα2 or OT-Ivβ5 chain into P14 TCR-Tg
58 T cells. Additionally, we observed that especially the P14vβ8
chain and OT-Ivα2 chain are prone to form mispaired TCR dimers
having a strong negative influence on correct P14 TCR pairing as
well as on the TCR expression level of involved TCR chains. This
may be due to still unknown intrinsic TCR properties and indi-
cates that the degree of TCR mispairing depends on the individual
TCR chain [30, 31]. In addition to reduced or even unequal TCR
surface expression levels, TCR mispairing contributed to the loss
of function of both TCRs in gene-modified T cells.
Two recent reports indicate that the formation of mispaired
TCR dimers can lead to autoimmunity [5, 6]. In these cases, the
introduction of a second cysteine bridge in the C-region of the Tg
TCR led to a reduction of harmful reactivity. In order to evaluate
the potential benefit of cysteineization for correct TCR chain
pairing in our model, we introduced this modification in the P14
TCR gene, since this TCR was most prone to a reduction in FRET
efficiency after induced OT-I TCR expression. In 58 T cells, we
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could not rescue the function of the P14 TCR by cysteineization
indicating that this modification alone is not sufficient to prevent
mispairing in this cell model. However in polyclonal T cells,
we detected little improvement in pairing of cysteineized and
codon-optimized P14 and OT-I TCR. A higher degree of correctly
paired TCRs resulted also in improved sensitivity of T-cell
responses as measured by IFN-γ release at low Ag concentrations.
These results are in agreement with previous reports showing on
one hand that codon optimization leads to a higher translation
rate of the Tg TCR, which then outpaces the endogenous TCR
in the competition for limited amounts of CD3 proteins. On the
other hand, the introduction of a second cysteine bridge in the
TCR C-region facilitates the correct pairing of the Tg TCR chains
and supports also efficient binding to the CD3 complex [13,14].
In sum, our results demonstrate that cysteineization of TCR
genes is not sufficient to completely avoid the formation of mis-
paired TCR dimers. Thus, other methods, which are recently
under development, to avoid the expression of endogenous TCRs
[32–34] should be used in the generation of TCR-Tg T cells for
TCR gene therapy.
Materials and methods
Cell lines and primary cells
The ecotropic packaging cell line PlatE [35] was grown in DMEM
(Gibco, Karlsruhe, Germany) with 10% FCS (Biochrom AG,
Berlin, Germany), 100 units/mL penicillin/streptomycin (Gibco),
and selective antibiotics (10 μg/mL blasticidin and 1 μg/mL
puromycin (Sigma-Aldrich, Taufkirchen, Germany)). The
58 murine T-cell line [21] was grown in RPMI 1640+GlutaMax1
medium (Gibco) with 10% heat-inactivated FCS (PAN Biotech,
Aidenbach, Germany), 100 units/mL penicillin/streptomycin,
and 10 mM HEPES (Sigma-Aldrich). Murine splenocytes were
grown in RPMI 1640+GlutaMax1 medium with 10% FCS (PAN
Biotech), 1 mM sodium pyruvate, 1% nonessential amino acids,
100 units/mL penicillin/streptomycin (all Gibco), 1 mM HEPES,
and 50 μM β-mercaptoethanol (Sigma-Aldrich).
Construction of TCR retrovirus vectors
The P14 TCR (vα2 = AV2S4 and vβ8 = BV8S1 [36]) is specific
for the lymphocytic choriomeningitis virus glycoprotein peptide
gp33–41 (gp33: KAVYNFATM) presented in an H2-Db-restricted
manner. P14 TCR gene cloning with twomyc tags (EQKLISEEDLE-
QKLISEEDL) at the N-terminus of the P14vα2 chain was described
[37]. The OT-I TCR (vα2 = AV2S2 and vβ5 = BV5S2) is spe-
cific for the H2-Kb-restricted OVA257–264 peptide (OVA: SIINFEKL)
[38,39]. The HA tag (YPYDVPDYA) was added to the N-terminus
of the OT-Ivα2 chain by PCR. The single TCR chains were intro-
duced into the MP71 vector [22] via NotI and EcoRI restriction
sites and afterwards cloned in the conformation of TCRvβ–P2A–
TCRvα as described [8]. TCR gene cassettes were blunt end ligated
into the LXSN retrovirus vector [22] using HpaI restriction site.
For the construction of the Tet-regulated MLV-SIN vector [20],
the TCR transgene cassettes were cloned into the SK-T2-lmg*
exchanging lmg transgene in SK-T2-lmg* and then, pTet-T2-TCR
was cloned into the MLV-SIN vector via XhoI and NotI restriction
sites. A second cysteine bridge was introduced by changing amino
acids 187 and 186 from a threonine into a cysteine in the P14 and
OT-I TCRvα chain, respectively, and amino acids 199 and 197 from
a serine into a cysteine in the P14 and OT-I TCRvβ chain, respec-
tively, by using overlapping PCRs. All primer sequences are pro-
vided on demand and primers were purchased from EurofinsMWG
Operon (Ebersberg, Germany). The codon-optimized P14 and
OT-I TCR genes were kindly provided by Jehad Charo (Berlin,
Germany) and Ton Schumacher (Amsterdam, Netherlands),
respectively.
Generation of TCR-Tg T cells
The 58 T-cell line and splenocytes were retrovirally transduced
as described [8]. For generation of Tet-regulated TCR-expressing
T-cell clones (either P14 or OT-I TCR), cells were incubated with
1 μg/mL Dox (Sigma-Aldrich) for 24 h, stained with TCRvβ-
specific mAb, and sorted as single cells into 96-well round bottom
plates (Corning Costar, Munich, Germany) using BD FACSAria
flow cytometer (BD Bioscience, Heidelberg, Germany). Growing
T-cell clones were analyzed for inducible TCR expression. One
chosen T-cell clone was retrovirally transduced with a second
TCR and single cell sorted for the TCRvβ chain expressed by the
LTCRSN vector.
After transduction of splenocytes from C57BL/6 mice (Charles
River, Sulzfeld, Germany), cells were cultured at a density of
1 × 106/mL with 10 ng/mL human recombinant IL-15
(PeproTech, Hamburg, Germany). All procedures were conducted
according to the institutional guidelines.
Flow cytometric analysis of TCR expression
For the induction of Tet-regulated TCR expression, T cells were
seeded at a density of 4 × 105/mL into a 24-well tissue cul-
ture plate with indicated Dox concentrations 24 h before anal-
ysis. For TCR staining following mAbs were used: anti-vα2 allo-
phycocyanin mAb (Caltag Laboratories, Karlsruhe, Germany) or
CD3ε allophycocyaninmAb (BD Pharmingen) in single TCR T cells,
anti-myc mAb (clone 9E10; purified from hybridoma supernatant
ATCC CRL-1729) or anti-HA mAb (clone 12CA; Roche Diagnos-
tics, Mannheim, Germany) for P14 or OT-I TCR, respectively, in
dual TCR T cells and transduced splenocytes, goat anti-mouse
IgG Cy5 Fab fragment (Jackson Immunoresearch, West Grove,
USA) for Tag staining, anti-TCRvβ8 PE or anti-TCRvβ5 PE mAb
(both BD Pharmingen) for P14 and OT-I TCR, respectively, in
single, dual TCR T cells and transduced splenocytes. For spleno-
cytes staining, Fc block CD16/CD32 (BD Pharmingen) was used in
advance.
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TCR chains were quantified using the Qifikit R© (Dako,
Eching, Germany), with primary mAbs for Tag of TCRvα chains
(as above) or with biotin-labeled mAbs for TCRvβ chains (BD
Pharmingen). Flow cytometric analysis was done with a FACS-
Calibur flow cytometer using CellQuest Pro software (both BD
Bioscience). Data analysis was performed with FlowJo software
(TreeStar, Ashland, USA).
Cytokine release assay
T cells and peptide-loaded murine splenocytes (irradiated with
30 gray), each 8 × 104, were co-cultured in a 96-well
round bottom plate for 24 h at 37◦C. Cell number of
TCR-transduced splenocytes and 58 T cells (for support-
ing information) was adjusted according to the transduction
rate. For 58 T-cell clones with Tet-regulated TCR expression,
Dox was added to the co-culture. For maximal stimulation,
5 ng/mL PMA (Sigma-Aldrich) and 1 μM ionomycin (Merck,
Darmstadt, Germany) were added. Harvested supernatants were
analyzed for secreted mouse IL-2 (eBioscience, San Diego, USA) of
58 T cells or for mouse IFN-γ (BD Bioscience) of splenocytes using
ELISA according to the manufacturer’s protocol. HPLC-purified
peptides (gp33–41: KAVYNFATM and OVA257–264: SIINFEKL) were
purchased from Biosynthan, Berlin, Germany.
Flow cytometry based FRET analysis
For FRET analysis, fluorescence intensities were measured using
a FACSCalibur dual-laser flow cytometer (BD Biosciences). Emis-
sions at 570 nm (donor channel, excitation at 488 nm), 670 nm
(acceptor channel, excitation at 635 nm), and over 670 nm (FRET
channel, excitation at 488 nm) were collected [11]. Data were
analyzed with the aFLEX software on a per cell basis [40].
Statistical analysis
Unpaired Student’s t-test was used to test statistical significance
between different groups with α = 0.05. p-Values were indi-
cated for significance with asterisks *p < 0.05, **p < 0.01, and
***p < 0.001. Measurements of duplicates were given as mean
and mean deviation. Measurements of multiple experiments or
triplets were given as mean ± SD.
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